Skip to main content
SpringerLink
Log in

Antibodies for Inflammatory Disease

Cytokines

  • Protocol
Diagnostic and Therapeutic Antibodies

Part of the book series: Methods in Molecular Medicine ((MIMM,volume 40))

Abstract

Cytokines are small proteins and major mediators of local intercellular communication required for an integrated response to a variety of stimuli in immune and inflammatory responses. By binding their cognate receptors on target cells, these short-lived molecules play a role in many important biological processes, including cell proliferation, activation, death, and differentiation. During an inflammatory response many cytokines are synthesized by a wide range of cell types, including leukocytes and fibroblasts. Some cytokines are proinflammatory, such as interleukin-1 (IL-1) and tumor necrosis factor a (TNF-α); others, such as interleukin-10 (IL-10) and transforming growth factor β(TGF-β), exert predominantly anti-inflammatory effects. However, it is now understood that many cytokines, for example, interferon-γ (IFN-γ), with chiefly proinflammatory activity, can also in some instances have anti-inflammatory properties. Similarly, cytokines with predominantly anti-inflammatory activity, such as IL-10 and TGF-β may also exhibit proinflammatory properties and therefore have pathogenic potential. Paracrine or autocrine pathways involving cytokines with either pro- or anti-inflammatory activity can lead to reverberating networks determining whether chronic inflammation results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, H., and Woody, J. N. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet344, 1105–1110.

    CAS  Google Scholar 

  2. Pincus, T. and Callahan, L. F. (1993) What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am.19, 123–151.

    CAS  Google Scholar 

  3. Sharp, J. T., Wolfe, F., Mitchell, D. M., and Bloch, D. A. (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum.34, 660–668.

    CAS  Google Scholar 

  4. Janossy, G., Panayi, G., Duke, O., Bofill, M., Poulter, L. W., and Goldstein, G. (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immuno-regulation. Lancetii, 839–841.

    Google Scholar 

  5. Cush, J. J. and Lipsky, P. E. (1988) Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum.31, 1230–1238.

    CAS  Google Scholar 

  6. Firestein, G. S. and Zvaifler, N. J. (1990) How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum.33, 768–773.

    CAS  Google Scholar 

  7. Miossec, P., Naviliat, M., D’Angeac, A. D., Sany, J., and Banchereau, J. (1990) Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum.33, 1180–1187.

    CAS  Google Scholar 

  8. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol.14, 397–440.

    CAS  Google Scholar 

  9. Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N., and Feldmann, M. (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-lα. Clin. Exp. Immunol.73, 449–455.

    CAS  Google Scholar 

  10. Brennan F. M., Chantry, D., Jackson, A., Maini R., and Feldmann, M. (1989) Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet2, 244–247.

    CAS  Google Scholar 

  11. Butler, D., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TFN-alpha antibody with the interleukin-1 receptorantagonist. Eur. Cytokine Netw.6(4), 225–230.

    CAS  Google Scholar 

  12. Dayer, J. M., Beutler, B., and Cerami, A. (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med.162, 2163–2168.

    CAS  Google Scholar 

  13. Katsikis, P. D., Chu, C. Q., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med.179, 1517–1527.

    CAS  Google Scholar 

  14. Fava, R., Olsen, N., Keski-Oja, J., Moses, H., and Pincus, T. (1989) Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med.169, 291–296.

    CAS  Google Scholar 

  15. Wahl, S. M. (1994) Transforming growth factor β: The good, the bad, and the ugly. J. Exp. Med.180, 1587–1590.

    CAS  Google Scholar 

  16. Cope, A. P., Aderka, D., Doherty, M., Engelmann, H., Gibbons, D., Jones, A. C., Brennan, F. M., Maini, R. N., Wallach, D., and Feldmann, M. (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum.35, 1160–1169.

    CAS  Google Scholar 

  17. Coley, W. (1893) The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci.105, 487–511.

    Google Scholar 

  18. Aggarwal, B. B., Kohr, W. J., Hass, P. E., Moffat, B., Spencer, S. A., Henzel, W. J., Bringman, T. S., Nedwin, G. E., Goeddel, D. V., and Harkins, R. N. (1985) Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem.260, 2345–2354.

    CAS  Google Scholar 

  19. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P.H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., and Goeddel, D. V. (1984) Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature312, 724–729.

    CAS  Google Scholar 

  20. Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., and Wallace, R. B. (1985) Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature313, 803–809.

    CAS  Google Scholar 

  21. Wang, A. M., Creasey, A. A., Ladner, M. B., Lin, L. S., Strickler, J., Van Arsdell, J. N., Yamamoto, R., and Mark, D. F. (1985) Molecular clongin of the comple-mentary DNA for human tumor necrosis factor. Science, 228, 149–154.

    CAS  Google Scholar 

  22. Beutler, B. and Cerami, A. (1986) Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature320, 584–588.

    CAS  Google Scholar 

  23. Jones, E. Y., Stuart, D. I., and Walker, N. P. C. (1989) Structure of tumour necrosis factor. Nature338, 225–228.

    CAS  Google Scholar 

  24. Bazzoni, F. and Beutler, B. (1996) The tumor necrosis factor ligand and receptor families (review). N. Engl. J. Med.334, 1717–1725.

    CAS  Google Scholar 

  25. Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D., and Wallach, D. (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem.264, 11,974–11,980.

    CAS  Google Scholar 

  26. Seckinger, P., Isaaz, S., and Dayer, J. M. (1988) A human inhibitor of tumor necrosis factor a. J. Exp. Med.167, 1511–1516.

    CAS  Google Scholar 

  27. Poltorak, A., Peppel, K., and Beutler, B. (1994) Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J. Immunol. Methods169, 93–99.

    CAS  Google Scholar 

  28. Tracey, K. J. and Cerami, A. (1994) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann. Rev. Med.45, 491–503.

    CAS  Google Scholar 

  29. Negussie, Y., Remick, D. G., DeForge, L. E., Kunkel, S. L., Eynon, A, and Griffin, G. E. (1992) Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J. Exp. Med.175, 1207–1212.

    CAS  Google Scholar 

  30. Chatenoud, L., Ferran, C., Reuter, A., Legendre, C., Gevaert, Y., Kreis, H., Franchimont, P., and Bach, J. F. (1989) Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N. Engl. J. Med.320, 1420,1421.

    Google Scholar 

  31. Dayer, J. M. and Burger, D (1994) Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw.5, 563–571.

    CAS  Google Scholar 

  32. Marchant, A., Bruyns, C., Vanderabeele, P., Ducarme, M., Gerard, C., Delvaux, A., De Groote, D., Abramowicz, D., Velu, T., and Goldman, M. (1994) Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol.24, 1167–1171.

    CAS  Google Scholar 

  33. Espevik, T., Figari, I. S., Shalaby, M. R., Lackides, G. A., Lewis, G. D., Shepard, H. M., and Palladino, M. A. J. (1987) Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med.166, 571–576.

    CAS  Google Scholar 

  34. Han, J., Thompson, P., and Beutler, B. (1990) Dexamethasone and pentoxifylline inhibit endotoxin induced TNF synthesis at separate points in their signaling pathway. J. Exp. Med.172, 391–394.

    CAS  Google Scholar 

  35. Parmely, M. J., Zhou, W. W., Edwards, C. K., Borcherding, D. R., Silverstein, R., and Morrison, D. C. (1993) Adenosine and a related cabocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J. Immunol.151, 389–396.

    CAS  Google Scholar 

  36. Bouma, M. G., Stad, R. K., van den Wildenberg, F. A., and Buurman, W. A. (1994) Differential regulatory efffects of adenosine on cytokine release by activated human monocytes. J. Immunol.153, 4159–4168.

    CAS  Google Scholar 

  37. Vannier, E., Miller, L. C., and Dinarello, C. A. (1991) Histamine suppressess gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors. J. Exp. Med.174, 281–284.

    CAS  Google Scholar 

  38. Florquin, S., Amraoui, Z., Dubois, C., Decuyper, J., and Goldman, M. (1994) The protective role of endogenously synthesized nitric oxide in staphylococcal entero-toxin B-induced shock in mice. J. Exp. Med.180, 1153–1158.

    CAS  Google Scholar 

  39. Eigler, A., Moeller, J., and Endres, S. (1995) Exogenous and endogenous nitric oxide attenuate tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J. Immunol.154, 4048–4054.

    CAS  Google Scholar 

  40. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med.177, 1675–1680.

    CAS  Google Scholar 

  41. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J.10, 4025–4031.

    CAS  Google Scholar 

  42. Williams, R. O., Feldmann, M., and Maini, R. N. (1992) Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA89, 9784–9788.

    CAS  Google Scholar 

  43. Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, A. M., Vilcek, J., Daddona, P., and Ghrayeb, J. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol.30, 1443–1453.

    CAS  Google Scholar 

  44. Winter, G. and Harris, W. J. (1993) Humanized antibodies. Immunol. Today14, 243–246.

    CAS  Google Scholar 

  45. Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., and Woody, J. N. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum.36, 1681–1690.

    CAS  Google Scholar 

  46. Paulus, H. E., Egger, M. J., Ward, J. R., Williams, H. J., and The Cooperative Systemic Studies of Rheumatic Diseases Group (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum.33, 477–484.

    CAS  Google Scholar 

  47. Feldmann, M., Elliott, M. J., Woody, J. N., and Maini, R. N. (1997) Anti-tumor necrosis factor-a therapy in rheumatoid arthritis. Adv. Immunol.64, 283–350.

    CAS  Google Scholar 

  48. Davis, D., Charles, P. J., Potter, A., Feldmann, M., Maini, R. N., and Elliott, M. J. (1997) Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor a. Br. J. Rheum.36, 950–956.

    CAS  Google Scholar 

  49. Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, H., and Woody, J. N. (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet344, 1125–1128.

    CAS  Google Scholar 

  50. Maini, R. N., Elliott, M. J., Brennan, F. M., Williams, R. O., Chu, C. Q., Paleolog, E., Charles, P. J., Taylor, P. C., and Feldmann, M. (1995) Monoclonal anti-TNFa antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev.144, 195–223.

    CAS  Google Scholar 

  51. Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MacFarlane, J. D., Antoni, C., Leeb, B., Elliott, M. J., Woody, J. N., Schaible, T. F., and Feldmann, M. (1997) Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFa antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum.40, S126.

    Google Scholar 

  52. Rankin, E. C. C., Choy, E. H. S., Kassimos, D., Kingsley, G. H., Sopwith, S. M., Isenberg, D. A., and Panayi, G. S. (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol.34, 334–342.

    CAS  Google Scholar 

  53. Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., Widmer, M. B., and Blosch, C. M. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med.337, 141–147.

    CAS  Google Scholar 

  54. Abraham, E., Wunderink, R., Silverman, H., Perl, T. M., Nasraway, S., Levy, H., Bone, R., Wenzel, R. P., Balk, R., Allred, R., et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis sydrome. A randomized, controlled, double-bline, multicenter, clinical trial. TNF-alpha mAb Sepsis Study Group. JAMA273, 934–941.

    CAS  Google Scholar 

  55. Fischer, C. J. Jr., Opal, S. M., Dhainaut, J.-F., Stephens, S., Zimmerman, J. L., Nightingale, P., Harris, S. J., Schein, R. M. H., Panacek, E. A., Vincent, J.-L., Foulke, G. E., Warren, E. L., Garrard, C., Park, G., Bodmer, M. W., Cohen, J., Van Der Linden, C., Cross, A. S., Sadoff, J. C., and The Cooperative Systemic Studies of Rheumatic Diseases Group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med.21, 318–327.

    Google Scholar 

  56. Reinhart, K., Wiegand-Lohnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S., Bouza, C., Krausch, D., Stockenhuber, F., Eiselstein, J., Daum, L., and Kempeni, J. (1996) Assessment of the safety and efficacy of the antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med.24, 733–742.

    CAS  Google Scholar 

  57. Fekade, D., Knox, K., Hussein, K., Melka, A., Lalloo, D. G., Coxon, R. E., and Warrell, D.A. (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N. Engl. J. Med.335, 311–315.

    CAS  Google Scholar 

  58. Van Dullemen, H. M., Van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., and Woody, J. (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109, 129–135.

    Google Scholar 

  59. McCabe, R. P., Woody, J. N., van Deventer, S., Targan, S. R., Mayer, L., van Hogezand, R., Rutgeerts, P., Hahauer, S. B., Podolsky, D., and Elson, C. O. (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology110(Suppl.), A962.

    Google Scholar 

  60. Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., and Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Disease. N. Engl. J. Med.337, 1029–1035.

    CAS  Google Scholar 

  61. Stack, W. A., Mann, S. D., Roy, A. J., Heath, P., Sopwith, M., Freeman, J., Holmes, G., Long, R., Forbes, A., and Kamm, M. A. (1997) Randomised con-trolled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet349, 521–524.

    CAS  Google Scholar 

  62. Charles, P., Potter, A., Elliott, M., Cope, A., Woody, J., Feldmann, M., and Maini, R. N. (1995) Regulation of sTNF-R and IL-6 following TNF blockade in RA: in vivo evidence for a cytokine cascade. Arthritis Rheum.38, S342.

    Google Scholar 

  63. Tak, P. P., Taylor, P. C., Breedveld, F. C., Smeets, T. J. M., Daha, M. R., Kluin, P. M., Meinders, A. E., and Maini, R. N. (1996) Decrease in cellularity and expres-sion of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum.39, 1077–1081.

    CAS  Google Scholar 

  64. Taylor, P. C., Maini, R. N., Tak, P. P., Breedveld, F. C., Smeets, T. J. M., Daha, M. R., Kluin, P. M., and Meinders, A. E. (1997) Reply to Decrease in cell adhe-sion molecules by treatment with anti-tumor necrosis factor a monoclonal antibody. Arthritis Rheum.4, 789–790.

    Google Scholar 

  65. Gearing, A. J. H. and Newman, W. (1993) Circulating adhesion molecules in dis-ease. Immunol. Today14, 506–512.

    CAS  Google Scholar 

  66. Leeuwenberg, J. F. M., Smeets, E. F., Neefjes, J. J., Shaffer, M. A., Cinek, T., Jeunhomme, T. M. A. A., and Buurman, W. A. (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology77, 543–549.

    CAS  PubMed  Google Scholar 

  67. Paleolog, E. M., Elliott, M. J., Woody, J. N., Feldmann, M., and Maini, R. N. (1996) Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum.39, 1082–1091.

    CAS  Google Scholar 

  68. Alvaro-Gracia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, K., and Firestein, G. S. (1991) Cytokines in chronic inflammatory arthritis. J. Immunol.146, 3365–3371.

    CAS  Google Scholar 

  69. Haworth, C., Brennan, F. M., Chantry, D., Turner, M., Maini, R. N., and Feldmann, M. (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α Eur. J. Immunol.21, 2575–2579.

    CAS  Google Scholar 

  70. Taylor, P. C., Chapman, P., Elliott, M. J., Schaible, T. F., Peter, A. M., Feldmann, M., and Maini, R. N. (1997) Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy. Arthritis Rheum.40, S80.

    Google Scholar 

  71. Paleolog, E. M., Young, S., Stark, A. C., McCloskey, R. V., Feldmann, M., and Maini, R. N. (1998) Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum.41, 1258–1265.

    CAS  Google Scholar 

  72. Gay, S., Gay, R. E., and Koopman W. J. (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction? Ann. Rheum. Dis.52, S39–S47.

    Google Scholar 

  73. Vanlent, P. L. E. M., Vandeloo, F. A. J., Holthuysen, A. E. M., Vandenbersselaar, A. M., Vermeer, H., and Vandenberg, W. B. (1995) Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J. Rheumatol.22, 2250–2258.

    CAS  Google Scholar 

  74. Brennan, F. M., Browne, K. A., Green, P. A., Jasper, J.-M., Maini, R. N., and Feldmann, M. (1997) Reduction of serum matrix metalloproteinase 1 and matrix: metalloproteinase 3 in RA patients following anti-TNFα (cA2) therapy. Br. J. Rheumatol.36, 643–650.

    CAS  Google Scholar 

  75. Wolfe, F., Mitchell, D. A., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., and Cathey, M. A. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum.37, 481–494.

    CAS  Google Scholar 

  76. Williams, R. O., Mason, L. M., Feldmann, M., and Maini, R. (1994) Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA91, 2762–2766.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Mathilda and Terence Kennedy Institute of Rheumatology, Hammersmith Hospital, London, UK

    Peter C. Taylor

Authors
  1. Peter C. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, Imperial College School of Medicine, Hammersmith Hospital, London, UK

    Andrew J. T. George

  2. Department of Pharmacology, University College, London, UK

    Catherine E. Urch

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc.

About this protocol

Cite this protocol

Taylor, P.C. (2000). Antibodies for Inflammatory Disease. In: George, A.J.T., Urch, C.E. (eds) Diagnostic and Therapeutic Antibodies. Methods in Molecular Medicine, vol 40. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-076-4:115

Download citation

  • DOI: https://doi.org/10.1385/1-59259-076-4:115

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-0-89603-798-4

  • Online ISBN: 978-1-59259-076-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation